News and Trends 6 Dec 2016 How is European Immuno-Oncology fighting Blood Cancer? From leukemia to multiple myeloma, biotech is working hard to cure blood cancer. This year’s edition of the American Society of Hematology (ASH) annual meeting features immuno-oncology therapies developed by the best European biotechs, with Novartis taking the lead in the CAR-T field. The 58th ASH annual meeting is wrapping up today, after the best companies […] December 6, 2016 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2016 New Private Placement to Boost the Profitable Therapeutic Antibody Market MorphoSys has announced a private placement of shares to raise funds for its antibody therapy programs. With this push, the company is solidifying its position as a leader in the therapeutic antibody market, which is expected to reach €117B by 2021. MorphoSys, one of the few European billion euro biotechs, develops therapeutic antibodies for immuno-oncology, inflammatory […] November 16, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2016 Antibody Therapies are here to Revolutionize Dermatology Leo Pharma is offering MorphoSys no less than €111.5M per antibody treatment with applications in dermatology, a very profitable field with big unmet needs. New cancer therapies might also arise from this exciting partnership! MorphoSys is a leader in the development of therapeutic antibodies with top-level partners like Novartis, Roche, Pfizer, Bayer, GSK, Galapagos […] November 2, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2016 New Psoriasis Antibody Therapy puts pressure on Best-Seller drug Humira New results from a Phase III trial show that guselkumab, an antibody therapy for the autoimmune disease plaque psoriasis, is performing better than the number one best-seller drug Humira (adalimumab) from AbbVie. The new drug is expected to be commercially available as early as 2018. Since MorphoSys licensed guselkumab to Janssen Biotech, in 2007, the drug has been performing […] October 5, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Apr 2016 ‘Disappointing results’ for Novartis & MorphoSys phase III in Muscle Disease MorphoSys confirms that its antibody (bimagrumab) failed to meet the primary endpoint of a phase IIb/III trial for a muscle disease (sIBM), conducted by Novartis. Sad news for Novartis and MorphoSys. The two companies are developing bimagrumab for muscle diseases, as part of their ongoing collaboration, which has already resulted in 11 programmes. Bimagrumab was initially […] April 27, 2016 - 2 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email